Conclusions
In our discipline, a huge amount of omics research has been employed
during recent years that needs to be analyzed in depth. Allergic
diseases are a group of complex and heterogeneous diseases. Specific,
sensitive and reliable (point-of-care) biomarkers are critical for
selecting the proper treatment for the proper patient and enabling
precision medicine. Precision endotyping is linking pathobiological
mechanisms with visible properties via specific biomarkers. It is
expected to be translated into pathway-specific diagnostic tests and
opens a pathway to accurate disease classification and individualized
targeted treatment options. We are expecting to change the diagnostic
and therapeutic landscape in our specialty as well as of all medical
disciplines. However, endotype-driven treatment still needs to face
multiple challenges before its implementation in daily practice in
allergic diseases and asthma. Most of the disease endotyping research is
conducted in severe forms of allergic diseases nowadays. Over the past
few years, the biomarker discovery field has gained great advances,
which facilitates the identification of novel methods for disease
diagnosis and therapy. With these fast-growing efforts, we can imagine
that in the near future, we will be able to find better ways to treat
allergic diseases, with a therapeutic approach targeted to the
individual patient.